Upstream Bio has become the latest biotech to chance ... It is joining the initial public offering (IPO) queue amid a flurry of IPO activity in the sector, with three biotechs listing on the ...

Completed enrollment of Phase 2 clinical trial of verekitug in patients with chronic rhinosinusitis with nasal polyps; top-line data expected ...

Between 2001 and 2023, approximately 24% of IPOs were from biotech and pharmaceutical companies. When MarketBeat Upstream Bio Is New On NASDAQ, Can Potentially Beat AstraZeneca's Asthma Drug On ...

eXoZymes, Inc. has announced that CEO Michael Heltzen and his team will ring the Nasdaq ... its successful IPO and progress in biotechnology by ringing the Nasdaq closing bell on February 19 ...